 | |
| Clinical data | |
|---|---|
| Trade names | Maxair |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a601096 |
| Pregnancy category |
|
| Routes of administration | Inhalational (MDI) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H20N2O3 |
| Molar mass | 240.303 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 N Y (what is this?) (verify) | |
Pirbuterol (trade nameMaxair) is a short-actingβ2 adrenoreceptor agonist withbronchodilating action used in the treatment ofasthma, available (as pirbuterol acetate) as a breath-activatedmetered-dose inhaler.
It was patented in 1971 and came into medical use in 1983.[1]
Pirbuterol is used in asthma for reversal of acutebronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrenttheophylline and/or inhaledcorticosteroid.[2][3]
After inhalation of doses up to 800μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized bycatechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.[2]
